

MALAYSIA

151st SESSION OF THE WHO EXECUTIVE BOARD GENEVA, SWITZERLAND 30TH MAY 2022

Agenda Item No. : 6.2

Title : Report on Hosted Partnerships

Intervention Note:

Thank you, Madam Chair.

Malaysia wishes to thank WHO for the report on the hosted partnerships.

Malaysia wishes to share with the Board that we have had a very outstanding partnership between the Drugs for Neglected Diseases *initiative* (DNDi) and the Foundation for Innovative New Diagnostics (FIND). This impactful partnership has generated evidence that supports policy change and has scaled up the point of care diagnosis and decentralised treatment of Hepatitis C in Malaysia. In addition to that, Ravidasvir used in combination therapy, was the first drug for Hepatitis C Virus that was developed through South-South collaboration with funding and clinical support from the Malaysian Government and non-profit organisations. This could not have been possible without strong political will and partnership.

It is evident, as illustrated in the report that these partnerships have benefited many Member States. Ultimately, political will and support from the government is crucial in addition to powerful effective partnerships. Malaysia takes note of this report.

Thank you Chair.